Effect of CPT-11 in combination with other anticancer agents in lung cancer cells

Anti-Cancer Drugs

Volumn 8, Issue 3, 1997, Pages 231-237

  Pei, Xin Hai ^a   Nakanishi, Yoichi ^a   Takayama, Koichi ^a   Bai, Feng ^a   Kawasaki, Masayuki ^a   Tsuruta, Nobuko ^a   Mizuno, Keiko ^a   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

anticancer agents; combination chemotherapy; CPT 11; in vitro; lung cancer

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; PACLITAXEL; TETRAZOLIUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0030887027     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199703000-00003     Document Type: Article

References (28)

1. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic. Cancer Res 1995; 55: 753-60.
2. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase 1 -DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
3. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
4. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 1983; 65: 55-63.
5. Nakanishi Y, Mulshine JL, Kasprzyk PG, et al. Insulinlike growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988; 82: 354-9.
6. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol 1979; 5: 85-91.
7. Kano Y, Suzuki K, Akutsu M, et al. Effect of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50: 604-10.
8. Negoro S, Fukuoka M, Masuda N, et al. Phase 1 study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-8.
9. Fukuoka M, Niitani H, Suzuki A, et al. A phase 2 study of CPT-11, a new derivative of camptothecin, for previous untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16-20.
10. Negoro S, Fukuoka M, Niitani H, Taguchi T. Phase 2 study of CPT-11, a new derivative of camptothecin, in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991; 10: 241.
11. Del Bino G, Darzynkiewicz Z. Camptothecin, teniposide, or 4′-(9-acridinylamino)-3-methanesufon-m-anisidide, but not mitoxantrone or doxorubicin. induces degradation of nuclear DNA in the S-phase of HL-60 cells. Cancer Res 1991; 51: 1165-9.
12. Ryan AJ, Squires S, Strutt HL, Evans A, Johnson RT. Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. Carcinogenesis 1994; 15: 823 8.
13. Liu LF. DNA topoisomerase poisons as anti-tumor drugs. Annu Rev Biochem 1989; 58: 351-75.
14. Sugimoto Y, Tsukahara S, Oh-hara T. Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase 2 in camptothecin-resistant human tumor cell lines. Cancer Res 1990; 50: 7962-5.
15. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T. Decreased expression of DNA topoisomerase 1 in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990; 50: 6925-30.
16. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992; 28A: 743-8.
17. Kaufmann SH. Antagonism between camptothecin and topoisomerase 2-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 1991; 51. 1129-36.
18. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1991; 50: 6919-24.
19. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase 1 and 2 in human tumor xenografts in nude mice, Int J Cancer 1992; 50: 760-6.
20. Tsutuo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1992; 21: 71-4.
21. Karata A, Sasaki Y, Shinkai T, et al. Phase 1 study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 1993; 11: 2030-5.
22. Nocentini G, Barzi A, Franchetti P. Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol 1990; 26: 345-51.
23. Zwelling IA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum (2) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979; 39: 365-9.
24. Kudoh S, Takada M, Mausda N, et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993; 84: 203-7.
25. Masuda N, Fukuoka M, Tokada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992; 10: 1775-80.
26. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-7.
27. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984; 25: 83-125.
28. Chou TC, Mortzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.